ZONTIVITY
Total Payments
$3.7M
Transactions
12,538
Doctors
4,076
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $150,553 | 1 | 0 |
| 2019 | $299,084 | 9 | 1 |
| 2018 | $1.1M | 3,980 | 2,070 |
| 2017 | $2.2M | 8,548 | 3,152 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 43 | 57.9% |
| Consulting Fee | $1.1M | 411 | 29.1% |
| Food and Beverage | $279,588 | 11,660 | 7.5% |
| Honoraria | $115,244 | 10 | 3.1% |
| Travel and Lodging | $90,208 | 356 | 2.4% |
| Education | $1,864 | 58 | 0.0% |
Payments by Type
Research
$2.2M
43 transactions
General
$1.6M
12,495 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Improving treatment of patients at high vascular risk | Merck Sharp & Dohme Corporation | $331,421 | 0 |
| Influence of Vorapaxar on Thrombin Generation and Coagulability | Merck Sharp & Dohme Corporation | $284,304 | 0 |
| Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation | Merck Sharp & Dohme Corporation | $177,114 | 0 |
| Adjunctive Vorapaxar Therapy in Patients with Prior Myocardial Infarction Treated with New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor VORA-PRATIC A Prospective, Randomized, Pharmacodynamic Study | Merck Sharp & Dohme Corporation | $153,377 | 0 |
| A double-blind, randomized, placebo-controlled study to determine the efficacy of suvorexant in the treatment of hot flash-associated insomnia in midlife women | Merck Sharp & Dohme Corporation | $149,754 | 0 |
| TRA added to Tadalafil in Pneumonectomy,MCT Model of PAH | Merck Sharp & Dohme Corporation | $145,531 | 0 |
| A double-blind, randomized, parallel design two center study to compare the effect of vorapaxar vs. placebo on lower extremity vein graft maturation, remodeling, and function in patients undergoing lower extremity revascularization for Rutherford 3, 4, or 5 peripheral artery disease. | Merck Sharp & Dohme Corporation | $121,500 | 0 |
| Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Post Myocardial Infarction Patients with and without Diabetes Mellitus the Prospective, Randomized, Cross-over Optimizing anti-Platelet Therapy In diabetes MellitUS OPTIMUS-5 Study | Merck Sharp & Dohme Corporation | $119,479 | 0 |
| Investigating shared-decision making Tools that are Evidence-based, with Greater Impact on Treatment Decision certainty in the Year following Peripheral Arterial Disease diagnosis INTEGRITY-PAD A Pilot Study | Merck Sharp & Dohme Corporation | $102,022 | 0 |
| Role of Par1 in the biology of the vessel wall | Merck Sharp & Dohme Corporation | $89,997 | 0 |
| Evaluation of the Effects of Vorapaxar in Combination with Aspirin on Platelet Functions in Atherosclerotic Arteries | Merck Sharp & Dohme Corporation | $74,006 | 0 |
| Temporal trends in the management and clinical outcomes of acute limb ischemia within a national Veteran population | Merck Sharp & Dohme Corporation | $70,222 | 0 |
| A double-blind, randomized, placebo controlled pilot trial to evaluate the safety and efficacy of vorapaxar in maturation of arteriovenous fistulae for hemodialysis access | Merck Sharp & Dohme Corporation | $52,795 | 0 |
| Temporal trends in the management and clinical outcomes of acute limb ischemia within a national Veteran population. | Merck Sharp & Dohme Corporation | $52,667 | 0 |
| Are Insomnia Symptoms Associated With Increased CSF Hypocretin-1 Levels - A Retrospective Pilot Study | Merck Sharp & Dohme Corporation | $50,086 | 0 |
| PAD - Medicare Study | Merck Sharp & Dohme Corporation | $48,657 | 0 |
| A phase Ib, open label, dose finding study to evaluate safety, pharmacodynamics, and efficacy of MK-3475 in combination with vorinostat in patients with advanced renal cell or urothelial cell carcinoma | Merck Sharp & Dohme Corporation | $45,029 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Crossover Pilot Study of Suvorexant for Insomnia in Parkinson Disease | Merck Sharp & Dohme Corporation | $41,773 | 0 |
| Secondary Analysis of Pre-existing Data and Biological Specimens. | Merck Sharp & Dohme Corporation | $41,689 | 0 |
| Risk Stratification | Merck Sharp & Dohme Corporation | $20,000 | 0 |
Top Doctors Receiving Payments for ZONTIVITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Falls Church, VA | $2.2M | 44 |
| , M. D | Internal Medicine | Conroe, TX | $59,378 | 54 |
| , M.D | Cardiovascular Disease | Oklahoma City, OK | $48,057 | 64 |
| , MD | Cardiovascular Disease | Brooklyn, NY | $41,140 | 53 |
| , MD | Interventional Cardiology | Birmingham, AL | $40,179 | 44 |
| , MD | Internal Medicine | Festus, MO | $34,104 | 73 |
| , MD | Internal Medicine | San Diego, CA | $30,814 | 28 |
| , MD | Cardiovascular Disease | Mission Hills, CA | $29,653 | 39 |
| , MD | Cardiovascular Disease | Nashville, TN | $29,321 | 18 |
| , MD | Nuclear Cardiology | Atlanta, GA | $29,294 | 39 |
| Mehrdad Ariani | Interventional Cardiology | Northridge, CA | $28,599 | 55 |
| , M.D | Cardiovascular Disease | Houston, TX | $27,757 | 29 |
| , M.D | Cardiovascular Disease | Sacramento, CA | $24,917 | 20 |
| , MD | Specialist | St Petersburg, FL | $24,301 | 31 |
| , D.O | Adult Congenital Heart Disease | New York, NY | $24,115 | 16 |
| , M.D | Nuclear Cardiology | New Brunswick, NJ | $22,002 | 26 |
| , M. D | Cardiovascular Disease | Jeffersonville, IN | $21,364 | 20 |
| , M.D | Cardiovascular Disease | Middletown, NJ | $21,138 | 32 |
| , M.D., MBA | Vascular Surgery | Milford, CT | $20,777 | 33 |
| , MD | Cardiovascular Disease | Boston, MA | $19,792 | 15 |
| Timothy Jayasundera | Cardiovascular Disease | New York, NY | $19,381 | 22 |
| , M.D | Cardiovascular Disease | Boston, MA | $17,557 | 8 |
| , MD | Cardiovascular Disease | Houston, TX | $17,380 | 38 |
| , MD | Vascular Surgery | Boston, MA | $17,144 | 8 |
| , MD | Cardiovascular Disease | Greeneville, TN | $17,081 | 22 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $2.2M
- Aralez Pharmaceuticals US Inc. $1.1M
- ARALEZ PHARMACEUTICALS US INC. $493,234
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 4,076
- Transactions 12,538
About ZONTIVITY
ZONTIVITY is a drug associated with $3.7M in payments to 4,076 healthcare providers, recorded across 12,538 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $150,553 was paid across 1 transactions to 0 doctors.
The most common payment nature for ZONTIVITY is "Unspecified" ($2.2M, 57.9% of total).
ZONTIVITY is associated with 20 research studies, including "Improving treatment of patients at high vascular risk" ($331,421).